BAGSVÆRD, Denmark, July 11, 2016 /PRNewswire/ --
This material is intended for global medical media only.
For journalistic assessment and preparation before publication.
Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia World Congress (WFH) in Orlando,
The broad spectrum of data demonstrates exciting new advances in the area of haemophilia and establishes Novo Nordisk's commitment to driving innovation and research. The comprehensive programme provides updates on Novo Nordisk's haemophilia pipeline, new clinical data regarding established treatments and insights into the psychosocial and functional impact of haemophilia on quality of life.
Following are key highlights that will be presented at the meeting:
Monday, July 25, 3:50 pm EDT, Poster Presentation
Tuesday, July 26, 3:30 pm EDT, Poster Presentations
Wednesday, July 27, 3:30 pm EDT, Poster Presentations
"The presentation of 28 abstracts at WFH 2016 is unparalleled and a clear signal to the haemophilia community that Novo Nordisk is committed to finding solutions to improve the lives of people living with haemophilia worldwide," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We look forward to the opportunity for scientific exchange at this important meeting."
The abstracts above are a sampling of the data that will be presented or published by Novo Nordisk. For a complete list of abstracts please visit: http://www.wfh.org/congress/2016_Abstracts
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information Media: Katrine Sperling +45-4442-6718 [email protected]
Åsa Josefsson +45-3079-7708 [email protected]
Courtney Mallon +1-609-786-4079 [email protected]
Investors: Peter Hugreffe Ankersen +45-3075-9085 [email protected]
Melanie Raouzeos +45-3075-3479 [email protected]
Kasper Veje (US) +1-609-235-8567 [email protected]
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All